首页 > 最新文献

Journal of intensive medicine最新文献

英文 中文
Severe asthma exacerbation: Changes in patient characteristics, management, and outcomes from 1997 to 2016 in 40 ICUs in the greater Paris area 严重哮喘加重:1997年至2016年大巴黎地区40所重症监护病房的患者特征、管理和治疗效果的变化
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.08.008
Romy Younan , Jean Loup Augy , Bertrand Hermann , Bertrand Guidet , Philippe Aegerter , Emmanuel Guerot , Ana Novara , Caroline Hauw-Berlemont , Amer Hamdan , Clotilde Bailleul , Francesca Santi , Jean-Luc Diehl , Nicolas Peron , Nadia Aissaoui

Background

Despite advances in asthma treatments, severe asthma exacerbation (SAE) remains a life-threatening condition in adults, and there is a lack of data derived from adult patients admitted to intensive care units (ICUs) for SAE. The current study investigated changes in adult patient characteristics, management, and outcomes of SAE over a 20-year period in 40 ICUs in the greater Paris area.

Methods

In this retrospective observational study, admissions to 40 ICUs in the greater Paris area for SAE from January 1, 1997, to December 31, 2016 were analyzed. The primary outcome was the proportion of ICU admissions for SAE during 5-year periods. Secondary outcomes were ICU and hospital mortality, and the use of mechanical ventilation and catecholamine. Multivariate analysis was performed to assess factors associated with ICU mortality.

Results

A total of 7049 admissions for SAE were recorded. For each 5-year period, the proportion decreased over time, with SAE accounting for 2.84% of total ICU admissions (n=2841) between 1997 and 2001, 1.76% (n=1717) between 2002 and 2006, 1.05% (n=965) between 2007 and 2011, and 1.05% (n=1526) between 2012 and 2016. The median age was 46 years (interquartile range [IQR]: 32–59 years), 55.41% were female, the median Simplified Acute Physiology Score II was 20 (IQR: 13–28), and 19.76% had mechanical ventilation. The use of mechanical ventilation remained infrequent throughout the 20-year period, whereas the use of catecholamine decreased. ICU and hospital mortality rates decreased. Factors associated with ICU mortality were renal replacement therapy, catecholamine, cardiac arrest, pneumothorax, acute respiratory distress syndrome, sepsis, and invasive mechanical ventilation (IMV). Non-survivors were older, had more severe symptoms, and were more likely to have received IMV.

Conclusion

ICU admission for SAE remains uncommon, and the proportion of cases decreased over time. Despite a slight increase in symptom severity during a 20-year period, ICU and hospital mortality decreased. Patients requiring IMV had a higher mortality rate.

背景尽管哮喘治疗方法不断进步,但严重哮喘加重(SAE)仍然是威胁成人生命的一种疾病,而且缺乏因严重哮喘加重而入住重症监护病房(ICU)的成人患者的相关数据。本研究调查了大巴黎地区 40 家重症监护病房在 20 年间因 SAE 入院的成人患者特征、管理和治疗效果的变化。主要结果是5年期间因SAE入住ICU的比例。次要结果是重症监护室和医院死亡率,以及机械通气和儿茶酚胺的使用情况。为评估与重症监护室死亡率相关的因素,进行了多变量分析。1997年至2001年间,SAE占ICU住院总人数的2.84%(n=2841);2002年至2006年间,SAE占ICU住院总人数的1.76%(n=1717);2007年至2011年间,SAE占ICU住院总人数的1.05%(n=965);2012年至2016年间,SAE占ICU住院总人数的1.05%(n=1526)。中位年龄为 46 岁(四分位间距 [IQR]:32-59 岁),55.41% 为女性,中位简化急性生理学评分 II 为 20(IQR:13-28),19.76% 使用机械通气。在这 20 年间,使用机械通气的情况仍然不多,而使用儿茶酚胺的情况则有所减少。重症监护室和医院死亡率均有所下降。与重症监护病房死亡率相关的因素包括肾脏替代治疗、儿茶酚胺、心脏骤停、气胸、急性呼吸窘迫综合征、败血症和有创机械通气(IMV)。非幸存者年龄更大、症状更严重、更有可能接受了有创机械通气。尽管在 20 年间症状的严重程度略有增加,但重症监护病房和医院的死亡率却有所下降。需要接受 IMV 治疗的患者死亡率较高。
{"title":"Severe asthma exacerbation: Changes in patient characteristics, management, and outcomes from 1997 to 2016 in 40 ICUs in the greater Paris area","authors":"Romy Younan ,&nbsp;Jean Loup Augy ,&nbsp;Bertrand Hermann ,&nbsp;Bertrand Guidet ,&nbsp;Philippe Aegerter ,&nbsp;Emmanuel Guerot ,&nbsp;Ana Novara ,&nbsp;Caroline Hauw-Berlemont ,&nbsp;Amer Hamdan ,&nbsp;Clotilde Bailleul ,&nbsp;Francesca Santi ,&nbsp;Jean-Luc Diehl ,&nbsp;Nicolas Peron ,&nbsp;Nadia Aissaoui","doi":"10.1016/j.jointm.2023.08.008","DOIUrl":"10.1016/j.jointm.2023.08.008","url":null,"abstract":"<div><h3>Background</h3><p>Despite advances in asthma treatments, severe asthma exacerbation (SAE) remains a life-threatening condition in adults, and there is a lack of data derived from adult patients admitted to intensive care units (ICUs) for SAE. The current study investigated changes in adult patient characteristics, management, and outcomes of SAE over a 20-year period in 40 ICUs in the greater Paris area.</p></div><div><h3>Methods</h3><p>In this retrospective observational study, admissions to 40 ICUs in the greater Paris area for SAE from January 1, 1997, to December 31, 2016 were analyzed. The primary outcome was the proportion of ICU admissions for SAE during 5-year periods. Secondary outcomes were ICU and hospital mortality, and the use of mechanical ventilation and catecholamine. Multivariate analysis was performed to assess factors associated with ICU mortality.</p></div><div><h3>Results</h3><p>A total of 7049 admissions for SAE were recorded. For each 5-year period, the proportion decreased over time, with SAE accounting for 2.84% of total ICU admissions (<em>n</em>=2841) between 1997 and 2001, 1.76% (<em>n</em>=1717) between 2002 and 2006, 1.05% (<em>n</em>=965) between 2007 and 2011, and 1.05% (<em>n</em>=1526) between 2012 and 2016. The median age was 46 years (interquartile range [IQR]: 32–59 years), 55.41% were female, the median Simplified Acute Physiology Score II was 20 (IQR: 13–28), and 19.76% had mechanical ventilation. The use of mechanical ventilation remained infrequent throughout the 20-year period, whereas the use of catecholamine decreased. ICU and hospital mortality rates decreased. Factors associated with ICU mortality were renal replacement therapy, catecholamine, cardiac arrest, pneumothorax, acute respiratory distress syndrome, sepsis, and invasive mechanical ventilation (IMV). Non-survivors were older, had more severe symptoms, and were more likely to have received IMV.</p></div><div><h3>Conclusion</h3><p>ICU admission for SAE remains uncommon, and the proportion of cases decreased over time. Despite a slight increase in symptom severity during a 20-year period, ICU and hospital mortality decreased. Patients requiring IMV had a higher mortality rate.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000786/pdfft?md5=e0ff932d3368a9ded6771ca7c84932a5&pid=1-s2.0-S2667100X23000786-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135762523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TRPV1: The key bridge in neuroimmune interactions TRPV1:神经免疫相互作用的关键桥梁
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2024.01.008

The nervous and immune systems are crucial in fighting infections and inflammation and in maintaining immune homeostasis. The immune and nervous systems are independent, yet tightly integrated and coordinated organizations. Numerous molecules and receptors play key roles in enabling communication between the two systems. Transient receptor potential vanilloid subfamily member 1 (TRPV1) is a non-selective cation channel, recently shown to be widely expressed in the neuroimmune axis and implicated in neuropathic pain, autoimmune disorders, and immune cell function. TRPV1 is a key bridge in neuroimmune interactions, allowing for smooth and convenient communication between the two systems. Here, we discuss the coordinated cross-talking between the immune and nervous systems and the functional role and the functioning manner of the TRPV1 involved. We suggest that TRPV1 provides new insights into the collaborative relationship between the nervous and immune systems, highlighting exciting opportunities for advanced therapeutic approaches to treating neurogenic inflammation and immune-mediated diseases.

神经系统和免疫系统在对抗感染和炎症以及维持免疫平衡方面至关重要。免疫系统和神经系统既相互独立,又紧密结合、相互协调。许多分子和受体在这两个系统之间的交流中发挥着关键作用。瞬时受体电位香草素亚族成员 1(TRPV1)是一种非选择性阳离子通道,最近被证明在神经免疫轴中广泛表达,并与神经性疼痛、自身免疫性疾病和免疫细胞功能有关。TRPV1 是神经免疫相互作用的关键桥梁,使两个系统之间的交流顺畅、便捷。在此,我们讨论了免疫系统和神经系统之间的协调性交叉对话,以及 TRPV1 的功能作用和运作方式。我们认为,TRPV1 为神经系统和免疫系统之间的协作关系提供了新的见解,为治疗神经源性炎症和免疫介导疾病的先进治疗方法提供了令人兴奋的机会。
{"title":"TRPV1: The key bridge in neuroimmune interactions","authors":"","doi":"10.1016/j.jointm.2024.01.008","DOIUrl":"10.1016/j.jointm.2024.01.008","url":null,"abstract":"<div><p>The nervous and immune systems are crucial in fighting infections and inflammation and in maintaining immune homeostasis. The immune and nervous systems are independent, yet tightly integrated and coordinated organizations. Numerous molecules and receptors play key roles in enabling communication between the two systems. Transient receptor potential vanilloid subfamily member 1 (TRPV1) is a non-selective cation channel, recently shown to be widely expressed in the neuroimmune axis and implicated in neuropathic pain, autoimmune disorders, and immune cell function. TRPV1 is a key bridge in neuroimmune interactions, allowing for smooth and convenient communication between the two systems. Here, we discuss the coordinated cross-talking between the immune and nervous systems and the functional role and the functioning manner of the TRPV1 involved. We suggest that TRPV1 provides new insights into the collaborative relationship between the nervous and immune systems, highlighting exciting opportunities for advanced therapeutic approaches to treating neurogenic inflammation and immune-mediated diseases.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X2400032X/pdfft?md5=c89ebda7d6bd06da8655c68eccce2495&pid=1-s2.0-S2667100X2400032X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140778434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latest developments in early diagnosis and specific treatment of severe influenza infection 重症流感感染的早期诊断和特异性治疗的最新进展
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.09.006
Francisco Valenzuela-Sánchez , Blanca Valenzuela-Méndez , Juan Francisco Rodríguez-Gutiérrez , Ángel Estella

Influenza pandemics are unpredictable recurrent events with global health, economic, and social consequences. The objective of this review is to provide an update on the latest developments in early diagnosis and specific treatment of the disease and its complications, particularly with regard to respiratory organ failure. Despite advances in treatment, the rate of mortality in the intensive care unit remains approximately 30%. Therefore, early identification of potentially severe viral pneumonia is extremely important to optimize treatment in these patients. The pathogenesis of influenza virus infection depends on viral virulence and host response. Thus, in some patients, it is associated with an excessive systemic response mediated by an authentic cytokine storm. This process leads to severe primary pneumonia and acute respiratory distress syndrome. Initial prognostication in the emergency department based on comorbidities, vital signs, and biomarkers (e.g., procalcitonin, ferritin, human leukocyte antigen-DR, mid-regional proadrenomedullin, and lactate) is important. Identification of these biomarkers on admission may facilitate clinical decision-making to determine early admission to the hospital or the intensive care unit. These decisions are reached considering pathophysiological circumstances that are associated with a poor prognosis (e.g., bacterial co-infection, hyperinflammation, immune paralysis, severe endothelial damage, organ dysfunction, and septic shock). Moreover, early implementation is important to increase treatment efficacy. Based on a limited level of evidence, all current guidelines recommend using oseltamivir in this setting. The possibility of drug resistance should also be considered. Alternative options include other antiviral drugs and combination therapies with monoclonal antibodies. Importantly, it is not recommended to use corticosteroids in the initial treatment of these patients. Furthermore, the implementation of supportive measures for respiratory failure is essential. Current recommendations are limited, heterogeneous, and not regularly updated. Early intubation and mechanical ventilation is the basic treatment for patients with severe respiratory failure. Prone ventilation should be promptly performed in patients with acute respiratory distress syndrome, while early tracheostomy should be considered in case of planned prolonged mechanical ventilation. Clinical trials on antiviral treatment and respiratory support measures specifically for these patients, as well as specific recommendations for different at-risk populations, are necessary to improve outcomes.

流感大流行是不可预测的经常性事件,会对全球健康、经济和社会造成影响。本综述旨在介绍该疾病及其并发症(尤其是呼吸器官衰竭)的早期诊断和具体治疗方面的最新进展。尽管在治疗方面取得了进步,但重症监护病房的死亡率仍约为 30%。因此,早期识别潜在的重症病毒性肺炎对优化这些患者的治疗极为重要。流感病毒感染的发病机制取决于病毒的毒性和宿主的反应。因此,有些患者会在真正的细胞因子风暴介导下出现过度的全身反应。这一过程会导致严重的原发性肺炎和急性呼吸窘迫综合征。在急诊科根据合并症、生命体征和生物标志物(如降钙素原、铁蛋白、人类白细胞抗原-DR、中区域前肾上腺髓质素和乳酸盐)来初步判断预后非常重要。入院时对这些生物标志物的鉴定有助于临床决策,以决定是否尽早入院或入住重症监护病房。做出这些决定时要考虑到与预后不良相关的病理生理情况(如细菌合并感染、炎症亢进、免疫麻痹、严重内皮损伤、器官功能障碍和脓毒性休克)。此外,尽早实施治疗对提高疗效也很重要。基于有限的证据,目前所有的指南都建议在这种情况下使用奥司他韦。此外,还应考虑耐药性的可能性。其他选择包括其他抗病毒药物和单克隆抗体联合疗法。重要的是,在对这些患者进行初始治疗时,不建议使用皮质类固醇。此外,对呼吸衰竭采取支持性措施也至关重要。目前的建议很有限,而且各不相同,也没有定期更新。早期插管和机械通气是治疗严重呼吸衰竭患者的基本方法。急性呼吸窘迫综合征患者应立即进行俯卧位通气,而在计划延长机械通气时间的情况下,应考虑尽早进行气管切开术。为改善治疗效果,有必要专门针对这些患者进行抗病毒治疗和呼吸支持措施的临床试验,并针对不同的高危人群提出具体建议。
{"title":"Latest developments in early diagnosis and specific treatment of severe influenza infection","authors":"Francisco Valenzuela-Sánchez ,&nbsp;Blanca Valenzuela-Méndez ,&nbsp;Juan Francisco Rodríguez-Gutiérrez ,&nbsp;Ángel Estella","doi":"10.1016/j.jointm.2023.09.006","DOIUrl":"10.1016/j.jointm.2023.09.006","url":null,"abstract":"<div><p>Influenza pandemics are unpredictable recurrent events with global health, economic, and social consequences. The objective of this review is to provide an update on the latest developments in early diagnosis and specific treatment of the disease and its complications, particularly with regard to respiratory organ failure. Despite advances in treatment, the rate of mortality in the intensive care unit remains approximately 30%. Therefore, early identification of potentially severe viral pneumonia is extremely important to optimize treatment in these patients. The pathogenesis of influenza virus infection depends on viral virulence and host response. Thus, in some patients, it is associated with an excessive systemic response mediated by an authentic cytokine storm. This process leads to severe primary pneumonia and acute respiratory distress syndrome. Initial prognostication in the emergency department based on comorbidities, vital signs, and biomarkers (e.g., procalcitonin, ferritin, human leukocyte antigen-DR, mid-regional proadrenomedullin, and lactate) is important. Identification of these biomarkers on admission may facilitate clinical decision-making to determine early admission to the hospital or the intensive care unit. These decisions are reached considering pathophysiological circumstances that are associated with a poor prognosis (e.g., bacterial co-infection, hyperinflammation, immune paralysis, severe endothelial damage, organ dysfunction, and septic shock). Moreover, early implementation is important to increase treatment efficacy. Based on a limited level of evidence, all current guidelines recommend using oseltamivir in this setting. The possibility of drug resistance should also be considered. Alternative options include other antiviral drugs and combination therapies with monoclonal antibodies. Importantly, it is not recommended to use corticosteroids in the initial treatment of these patients. Furthermore, the implementation of supportive measures for respiratory failure is essential. Current recommendations are limited, heterogeneous, and not regularly updated. Early intubation and mechanical ventilation is the basic treatment for patients with severe respiratory failure. Prone ventilation should be promptly performed in patients with acute respiratory distress syndrome, while early tracheostomy should be considered in case of planned prolonged mechanical ventilation. Clinical trials on antiviral treatment and respiratory support measures specifically for these patients, as well as specific recommendations for different at-risk populations, are necessary to improve outcomes.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000877/pdfft?md5=e1f9c2697cfdf935c044147d0184f6ad&pid=1-s2.0-S2667100X23000877-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139020599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Th17/Treg cell balance on length of stay in intensive care units of patients with sepsis 预测 Th17/Treg 细胞平衡对脓毒症患者重症监护室住院时间的影响
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.09.005
Yu Wu , Guosheng Wu , Minyu Li , Yongqing Chang , Miao Yu , Yan Meng , Xiaojian Wan

Background

Prolonged length of stay (LOS) of sepsis can drain a hospital's material and human resources. This study investigated the correlations between T helper type 17 (Th17) and regulatory T (Treg) balance with LOS in sepsis.

Methods

A prospective clinical observational study was designed in Changhai Hospital affiliated to Naval Medical University in Shanghai, China, from January to October 2020. The patients diagnosed with sepsis and who met the inclusion and exclusion criteria were recruited and whether the levels of cytokines, procalcitonin, subtypes, and biomarkers of T cells in the peripheral blood were detected. We analyzed the correlation between these and LOS.

Results

Sixty septic patients were classified into two groups according to whether their intensive care unit (ICU) stay exceeded 14 days. The patients with LOS ≥14 days were older ([72.6±7.5] years vs. [63.3±10.4] years, P=0.015) and had higher Sequential Organ Failure Assessment (SOFA) (median [interquartile range]: 6.5 [5.0–11.0] vs. 4.0 [3.0–6.0], P=0.001) and higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores (16.0 [13.0–21.0] vs. 8.5 [7.0–14.0], P=0.001). There was no difference in other demographic characteristics and cytokines, interleukin-6, tumor necrosis factor-α, and interleukin-10 between the two groups. The Th17/Treg ratio of sepsis with LOS <14 days was considerably lower (0.48 [0.38–0.56] vs. 0.69 [0.51–0.98], P=0.001). For patients with LOS ≥14 days, the area under the receiver operating characteristic curve for the Th17/Treg ratio was 0.766. It improved to 0.840 and 0.850 when combined with the SOFA and APACHE II scores, respectively.

Conclusions

The Th17/Treg ratio was proportional to septic severity and can be used as a potential predictor of ICU stay in sepsis, presenting a new option for ICU practitioners to better care for patients with sepsis.

背景脓毒症患者住院时间(LOS)的延长会耗费医院的物力和人力。本研究探讨了脓毒症患者T辅助细胞17型(Th17)和调节性T(Treg)平衡与住院时间的相关性。方法于2020年1月至10月在中国上海海军军医大学附属长海医院设计了一项前瞻性临床观察研究。招募符合纳入和排除标准的脓毒症患者,检测其外周血中细胞因子、降钙素原、亚型和 T 细胞生物标志物的水平。结果根据脓毒症患者在重症监护室(ICU)的住院时间是否超过 14 天,将其分为两组。LOS≥14天的患者年龄较大([72.6±7.5] 岁 vs. [63.3±10.4]岁,P=0.015),序贯器官功能衰竭评估(SOFA)较高(中位数[四分位间范围]:6.5[5.0-11.0]对 4.0 [3.0-6.0],P=0.001),急性生理学和慢性健康评估(APACHE)II 评分更高(16.0 [13.0-21.0] 对 8.5 [7.0-14.0],P=0.001)。两组患者的其他人口统计学特征和细胞因子、白细胞介素-6、肿瘤坏死因子-α和白细胞介素-10均无差异。LOS<14天的脓毒症患者的Th17/Treg比值要低得多(0.48 [0.38-0.56] vs. 0.69 [0.51-0.98],P=0.001)。对于LOS≥14天的患者,Th17/Treg比值的接收者操作特征曲线下面积为0.766。结论 Th17/Treg 比值与脓毒症严重程度成正比,可作为脓毒症患者入住 ICU 的潜在预测指标,为 ICU 医生更好地护理脓毒症患者提供了新的选择。
{"title":"Prediction of Th17/Treg cell balance on length of stay in intensive care units of patients with sepsis","authors":"Yu Wu ,&nbsp;Guosheng Wu ,&nbsp;Minyu Li ,&nbsp;Yongqing Chang ,&nbsp;Miao Yu ,&nbsp;Yan Meng ,&nbsp;Xiaojian Wan","doi":"10.1016/j.jointm.2023.09.005","DOIUrl":"10.1016/j.jointm.2023.09.005","url":null,"abstract":"<div><h3>Background</h3><p>Prolonged length of stay (LOS) of sepsis can drain a hospital's material and human resources. This study investigated the correlations between T helper type 17 (Th17) and regulatory T (Treg) balance with LOS in sepsis.</p></div><div><h3>Methods</h3><p>A prospective clinical observational study was designed in Changhai Hospital affiliated to Naval Medical University in Shanghai, China, from January to October 2020. The patients diagnosed with sepsis and who met the inclusion and exclusion criteria were recruited and whether the levels of cytokines, procalcitonin, subtypes, and biomarkers of T cells in the peripheral blood were detected. We analyzed the correlation between these and LOS.</p></div><div><h3>Results</h3><p>Sixty septic patients were classified into two groups according to whether their intensive care unit (ICU) stay exceeded 14 days. The patients with LOS ≥14 days were older ([72.6±7.5] years <em>vs</em>. [63.3±10.4] years, <em>P</em>=0.015) and had higher Sequential Organ Failure Assessment (SOFA) (median [interquartile range]: 6.5 [5.0–11.0] <em>vs</em>. 4.0 [3.0–6.0], <em>P</em>=0.001) and higher Acute Physiology and Chronic Health Evaluation (APACHE) II scores (16.0 [13.0–21.0] <em>vs</em>. 8.5 [7.0–14.0], <em>P</em>=0.001). There was no difference in other demographic characteristics and cytokines, interleukin-6, tumor necrosis factor-α, and interleukin-10 between the two groups. The Th17/Treg ratio of sepsis with LOS &lt;14 days was considerably lower (0.48 [0.38–0.56] <em>vs</em>. 0.69 [0.51–0.98], <em>P</em>=0.001). For patients with LOS ≥14 days, the area under the receiver operating characteristic curve for the Th17/Treg ratio was 0.766. It improved to 0.840 and 0.850 when combined with the SOFA and APACHE II scores, respectively.</p></div><div><h3>Conclusions</h3><p>The Th17/Treg ratio was proportional to septic severity and can be used as a potential predictor of ICU stay in sepsis, presenting a new option for ICU practitioners to better care for patients with sepsis.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000853/pdfft?md5=321ab9d2b5242e0e171ec49293fa0b44&pid=1-s2.0-S2667100X23000853-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138993281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts 糖皮质激素治疗急性呼吸窘迫综合征:当前概念
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2024.02.002

Acute respiratory distress syndrome (ARDS), a fatal critical disease, is induced by various insults. ARDS represents a major global public health burden, and the management of ARDS continues to challenge healthcare systems globally, especially during the pandemic of the coronavirus disease 2019 (COVID-19). There remains no confirmed specific pharmacotherapy for ARDS, despite advances in understanding its pathophysiology. Debate continues about the potential role of glucocorticoids (GCs) as a promising ARDS clinical therapy. Questions regarding GC agent, dose, and duration in patients with ARDS need to be answered, because of substantial variations in GC administration regimens across studies. ARDS heterogeneity likely affects the therapeutic actions of exogenous GCs. This review includes progress in determining the GC mechanisms of action and clinical applications in ARDS, especially during the COVID-19 pandemic.

急性呼吸窘迫综合征(ARDS)是一种致命的危重疾病,由各种损伤诱发。ARDS 是全球公共卫生的主要负担,ARDS 的管理继续对全球医疗保健系统构成挑战,尤其是在 2019 年冠状病毒病(COVID-19)大流行期间。尽管人们对 ARDS 的病理生理学有了更深入的了解,但目前仍未确定针对 ARDS 的特效药物疗法。关于糖皮质激素(GCs)作为一种有前景的 ARDS 临床疗法的潜在作用的争论仍在继续。有关 ARDS 患者使用糖皮质激素的药物、剂量和持续时间等问题亟待解决,因为不同研究的糖皮质激素给药方案存在很大差异。ARDS 的异质性可能会影响外源性 GCs 的治疗作用。本综述包括确定 GC 作用机制的进展以及在 ARDS 中的临床应用,尤其是在 COVID-19 大流行期间。
{"title":"Glucocorticoid therapy for acute respiratory distress syndrome: Current concepts","authors":"","doi":"10.1016/j.jointm.2024.02.002","DOIUrl":"10.1016/j.jointm.2024.02.002","url":null,"abstract":"<div><p>Acute respiratory distress syndrome (ARDS), a fatal critical disease, is induced by various insults. ARDS represents a major global public health burden, and the management of ARDS continues to challenge healthcare systems globally, especially during the pandemic of the coronavirus disease 2019 (COVID-19). There remains no confirmed specific pharmacotherapy for ARDS, despite advances in understanding its pathophysiology. Debate continues about the potential role of glucocorticoids (GCs) as a promising ARDS clinical therapy. Questions regarding GC agent, dose, and duration in patients with ARDS need to be answered, because of substantial variations in GC administration regimens across studies. ARDS heterogeneity likely affects the therapeutic actions of exogenous GCs. This review includes progress in determining the GC mechanisms of action and clinical applications in ARDS, especially during the COVID-19 pandemic.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X24000331/pdfft?md5=1311ef563468151d4818f26145e2e53e&pid=1-s2.0-S2667100X24000331-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140790963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of time-varying dead space estimates in mechanically ventilated patients with acute respiratory distress syndrome 急性呼吸窘迫综合征机械通气患者时变死腔估计值的预后价值
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.08.002
Lianlian Jiang , Hui Chen , Jianfeng Xie , Ling Liu , Yi Yang

Background

The dead space fraction (VD/VT) has proven to be a powerful predictor of higher mortality in acute respiratory distress syndrome (ARDS). However, its measurement relies on expired carbon dioxide, limiting its widespread application in clinical practice. Several estimates employing routine variables have been found to be reliable substitutes for direct measurement of VD/VT. In this study, we evaluated the prognostic value of these dead space estimates obtained in the first 7 days following the initiation of ventilation.

Methods

This retrospective observational study was conducted using data from the Chinese database in intensive care (CDIC). Eligible participants were adult ARDS patients receiving invasive mechanical ventilation while in the intensive care unit between 1st January 2014 and 31st March 2021. We collected data during the first 7 days of ventilation to calculate various dead space estimates, including ventilatory ratio (VR), corrected minute ventilation (V˙Ecorr), VD/VT (Harris–Benedict), VD/VT (Siddiki estimate), and VD/VT (Penn State estimate) longitudinally. A time-dependent Cox model was used to handle these time-varying estimates.

Results

A total of 392 patients (median age 66 [interquartile range: 55–77] years, median SOFA score 9 [interquartile range: 7–12]) were finally included in our analysis, among whom 132 (33.7%) patients died within 28 days of admission. VR (hazard ratio [HR]=1.04 per 0.1 increase, 95% confidence interval [CI]: 1.01 to 1.06; P=0.013), V˙Ecorr (HR=1.08 per 1 increase, 95% CI: 1.04 to 1.12; P < 0.001), VD/VT (Harris–Benedict) (HR=1.25 per 0.1 increase, 95% CI: 1.06 to 1.47; P=0.006), and VD/VT (Penn State estimate) (HR=1.22 per 0.1 increase, 95% CI: 1.04 to 1.44; P=0.017) remained significant after adjustment, while VD/VT (Siddiki estimate) (HR=1.10 per 0.1 increase, 95% CI: 1.00 to 1.20; P=0.058) did not. Given a large number of negative values, VD/VT (Siddiki estimate) and VD/VT (Penn State estimate) were not recommended as reliable substitutes. Long-term exposure to VR >1.3, V˙Ecorr >7.53, and VD/VT (Harris–Benedict) >0.59 was independently associated with an increased risk of mortality in ARDS patients. These findings were validated in the fluid and catheter treatment trial (FACTT) database.

Conclusions

In cases where VD/VT cannot

背景事实证明,死腔分数(VD/VT)是预测急性呼吸窘迫综合征(ARDS)死亡率的有力指标。然而,其测量依赖于呼出的二氧化碳,限制了其在临床实践中的广泛应用。研究发现,一些采用常规变量的估算值可以可靠地替代 VD/VT 的直接测量值。在本研究中,我们评估了这些死腔估计值在开始通气后头 7 天内的预后价值。方法这项回顾性观察研究使用了中国重症监护数据库(CDIC)中的数据。符合条件的参与者为 2014 年 1 月 1 日至 2021 年 3 月 31 日期间在重症监护病房接受有创机械通气的成年 ARDS 患者。我们收集了通气最初 7 天的数据,以纵向计算各种死腔估计值,包括通气比(VR)、校正分钟通气量(V˙Ecorr)、VD/VT(Harris-Benedict)、VD/VT(Siddiki 估计值)和 VD/VT(宾夕法尼亚州估计值)。结果 共有 392 名患者(中位年龄 66 [四分位间距:55-77]岁,中位 SOFA 评分 9 [四分位间距:7-12])被纳入我们的分析,其中 132 名患者(33.7%)在入院 28 天内死亡。VR(每增加 0.1,危险比 [HR] =1.04,95% 置信区间 [CI]:1.01 至 1.06;每增加 0.1,危险比 [HR] =1.04,95% 置信区间 [CI]:1.011.01至1.06;P=0.013)、V˙Ecorr(每增加1,HR=1.08,95% CI:1.04至1.12;P <;0.001)、VD/VT(Harris-Benedict)(每增加0.1,HR=1.25,95% CI:1.06至1.47;P=0.006)和VD/VT(宾夕法尼亚州估计)(每增加0.1,HR=1.每增加 0.1,HR=1.22,95% CI:1.04 至 1.44;P=0.017)经调整后仍具有显著性,而 VD/VT(Siddiki 估计值)(每增加 0.1,HR=1.10,95% CI:1.00 至 1.20;P=0.058)则不具有显著性。由于存在大量负值,因此不建议将 VD/VT(Siddiki 估计值)和 VD/VT(宾夕法尼亚州估计值)作为可靠的替代品。长期暴露于 VR >1.3、V˙Ecorr >7.53、VD/VT(Harris-Benedict)>0.59 与 ARDS 患者死亡风险增加有独立关联。结论在无法直接测量 VD/VT 的情况下,VR、V˙Ecorr 和 VD/VT (Harris-Benedict) 等 VD/VT 的早期时变估计值可用于预测 ARDS 患者的死亡率,从而提供快速的床边应用。
{"title":"Prognostic value of time-varying dead space estimates in mechanically ventilated patients with acute respiratory distress syndrome","authors":"Lianlian Jiang ,&nbsp;Hui Chen ,&nbsp;Jianfeng Xie ,&nbsp;Ling Liu ,&nbsp;Yi Yang","doi":"10.1016/j.jointm.2023.08.002","DOIUrl":"10.1016/j.jointm.2023.08.002","url":null,"abstract":"<div><h3>Background</h3><p>The dead space fraction (V<sub>D</sub>/V<sub>T</sub>) has proven to be a powerful predictor of higher mortality in acute respiratory distress syndrome (ARDS). However, its measurement relies on expired carbon dioxide, limiting its widespread application in clinical practice. Several estimates employing routine variables have been found to be reliable substitutes for direct measurement of V<sub>D</sub>/V<sub>T</sub>. In this study, we evaluated the prognostic value of these dead space estimates obtained in the first 7 days following the initiation of ventilation.</p></div><div><h3>Methods</h3><p>This retrospective observational study was conducted using data from the Chinese database in intensive care (CDIC). Eligible participants were adult ARDS patients receiving invasive mechanical ventilation while in the intensive care unit between 1st January 2014 and 31st March 2021. We collected data during the first 7 days of ventilation to calculate various dead space estimates, including ventilatory ratio (VR), corrected minute ventilation (<span><math><msub><mover><mi>V</mi><mo>˙</mo></mover><mtext>Ecorr</mtext></msub></math></span>), V<sub>D</sub>/V<sub>T</sub> (Harris–Benedict), V<sub>D</sub>/V<sub>T</sub> (Siddiki estimate), and V<sub>D</sub>/V<sub>T</sub> (Penn State estimate) longitudinally. A time-dependent Cox model was used to handle these time-varying estimates.</p></div><div><h3>Results</h3><p>A total of 392 patients (median age 66 [interquartile range: 55–77] years, median SOFA score 9 [interquartile range: 7–12]) were finally included in our analysis, among whom 132 (33.7%) patients died within 28 days of admission. VR (hazard ratio [HR]=1.04 per 0.1 increase, 95% confidence interval [CI]: 1.01 to 1.06; <em>P</em>=0.013), <span><math><msub><mover><mi>V</mi><mo>˙</mo></mover><mtext>Ecorr</mtext></msub></math></span> (HR=1.08 per 1 increase, 95% CI: 1.04 to 1.12; <em>P</em> &lt; 0.001), V<sub>D</sub>/V<sub>T</sub> (Harris–Benedict) (HR=1.25 per 0.1 increase, 95% CI: 1.06 to 1.47; <em>P</em>=0.006), and V<sub>D</sub>/V<sub>T</sub> (Penn State estimate) (HR=1.22 per 0.1 increase, 95% CI: 1.04 to 1.44; <em>P</em>=0.017) remained significant after adjustment, while V<sub>D</sub>/V<sub>T</sub> (Siddiki estimate) (HR=1.10 per 0.1 increase, 95% CI: 1.00 to 1.20; <em>P</em>=0.058) did not. Given a large number of negative values, V<sub>D</sub>/V<sub>T</sub> (Siddiki estimate) and V<sub>D</sub>/V<sub>T</sub> (Penn State estimate) were not recommended as reliable substitutes. Long-term exposure to VR &gt;1.3, <span><math><msub><mover><mi>V</mi><mo>˙</mo></mover><mtext>Ecorr</mtext></msub></math></span> &gt;7.53, and V<sub>D</sub>/V<sub>T</sub> (Harris–Benedict) &gt;0.59 was independently associated with an increased risk of mortality in ARDS patients. These findings were validated in the fluid and catheter treatment trial (FACTT) database.</p></div><div><h3>Conclusions</h3><p>In cases where V<sub>D</sub>/V<sub>T</sub> cannot ","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000579/pdfft?md5=0ac9da0cfca8c02b622234d8102decc2&pid=1-s2.0-S2667100X23000579-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective analysis of carbapenem-resistant Acinetobacter baumannii infections in critically ill patients: Experience at a tertiary-care teaching hospital ICU 重症患者中耐碳青霉烯类鲍曼不动杆菌感染的回顾性分析:一家三级教学医院重症监护室的经验
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.11.004
Leyla Ferlicolak , Neriman Defne Altintas , Fugen Yoruk

Background

Acinetobacter baumannii is a clinically significant pathogen with a high incidence of multidrug resistance that is associated with life-threatening nosocomial infections. Here, we aimed to provide an insight into the clinical characteristics and outcomes of a unique group of A. baumannii infections in which the isolates were resistant to carbapenems and most other antibiotic groups in a tertiary-care intensive care unit (ICU).

Methods

We performed a retrospective observational study in which records of patients hospitalized in the ICU between June 1, 2021 and June 1, 2023 were reviewed. We checked the clinical, laboratory, and microbiological records of all adult patients who had carbapenem-resistant A. baumannii (CRAB) infections. Prior antibiotic treatments and definitive antibiotic treatments after culture positivity and susceptibility test results were recorded. C-reactive protein (CRP) and procalcitonin levels and leukocyte counts were noted. Length of ICU stay and 30-day mortality were defined as the outcome parameters.

Results

During the study period, 57 patients were diagnosed with CRAB infections. The respiratory tract was the leading infection site (80.7%). In non-survivors, bloodstream infections (21.9% vs. 4.0% P=0.05) and colistin-resistant (col-R) CRAB infections (43.8% vs. 24.0%, P=0.12) were more common than in survivors, but these parameters were not statistically significant. The length of ICU stay was not different between survivors and non-survivors. Overall, the rate of col-R among CRAB clinical isolates was 35.1%. The 30-day mortality in all patients with CRAB infection was 56.1%. Mortality in col-R CRAB and colistin-susceptible (col-S) CRAB infections was 70.0% and 48.6%, respectively (P=0.12). Prior carbapenem use was 56.1%. Prior colistin use before col-R and col-S CRAB infections was not significant (35.0% vs. 27.0%, P=0.53).

Conclusions

Our study provides real-world data on highly resistant A. baumannii infections and shares the characteristics of infections with such resistant strains. Unfortunately, carbapenem resistance in A. baumannii is a challenge for intensive care specialists who are faced with few treatment options, and colistin resistance further complicates the problem.

背景鲍曼不动杆菌是一种临床意义重大的病原体,对多种药物耐药的发生率很高,与危及生命的院内感染有关。方法 我们开展了一项回顾性观察研究,审查了 2021 年 6 月 1 日至 2023 年 6 月 1 日期间在重症监护病房住院的患者记录。我们检查了所有耐碳青霉烯类鲍曼尼菌(CRAB)感染的成人患者的临床、实验室和微生物学记录。记录了之前的抗生素治疗和培养阳性后的最终抗生素治疗以及药敏试验结果。记录了 C 反应蛋白 (CRP) 和降钙素原水平以及白细胞计数。重症监护室住院时间和 30 天死亡率被定义为结果参数。呼吸道是主要感染部位(80.7%)。在非幸存者中,血流感染(21.9% 对 4.0%,P=0.05)和耐可乐定(col-R)CRAB 感染(43.8% 对 24.0%,P=0.12)比幸存者更常见,但这些参数没有统计学意义。幸存者和非幸存者在重症监护室的住院时间没有差异。总体而言,CRAB 临床分离株的 col-R 感染率为 35.1%。所有CRAB感染患者的30天死亡率为56.1%。在col-R CRAB和对可乐定敏感(col-S)的CRAB感染中,死亡率分别为70.0%和48.6%(P=0.12)。之前使用碳青霉烯类药物的比例为 56.1%。我们的研究提供了高耐药鲍曼不动杆菌感染的真实数据,并与此类耐药菌株的感染特征相同。不幸的是,鲍曼不动杆菌对碳青霉烯类耐药是重症监护专家面临的一个挑战,因为他们面临的治疗选择很少,而对可乐定耐药则使问题进一步复杂化。
{"title":"A retrospective analysis of carbapenem-resistant Acinetobacter baumannii infections in critically ill patients: Experience at a tertiary-care teaching hospital ICU","authors":"Leyla Ferlicolak ,&nbsp;Neriman Defne Altintas ,&nbsp;Fugen Yoruk","doi":"10.1016/j.jointm.2023.11.004","DOIUrl":"10.1016/j.jointm.2023.11.004","url":null,"abstract":"<div><h3>Background</h3><p><em>Acinetobacter baumannii</em> is a clinically significant pathogen with a high incidence of multidrug resistance that is associated with life-threatening nosocomial infections. Here, we aimed to provide an insight into the clinical characteristics and outcomes of a unique group of <em>A. baumannii</em> infections in which the isolates were resistant to carbapenems and most other antibiotic groups in a tertiary-care intensive care unit (ICU).</p></div><div><h3>Methods</h3><p>We performed a retrospective observational study in which records of patients hospitalized in the ICU between June 1, 2021 and June 1, 2023 were reviewed. We checked the clinical, laboratory, and microbiological records of all adult patients who had carbapenem-resistant <em>A. baumannii</em> (CRAB) infections. Prior antibiotic treatments and definitive antibiotic treatments after culture positivity and susceptibility test results were recorded<strong>.</strong> C-reactive protein (CRP) and procalcitonin levels and leukocyte counts were noted. Length of ICU stay and 30-day mortality were defined as the outcome parameters.</p></div><div><h3>Results</h3><p>During the study period, 57 patients were diagnosed with CRAB infections. The respiratory tract was the leading infection site (80.7%). In non-survivors, bloodstream infections (21.9% <em>vs.</em> 4.0% <em>P</em>=0.05) and colistin-resistant (col-R) CRAB infections (43.8% <em>vs.</em> 24.0%, <em>P</em>=0.12) were more common than in survivors, but these parameters were not statistically significant. The length of ICU stay was not different between survivors and non-survivors. Overall, the rate of col-R among CRAB clinical isolates was 35.1%. The 30-day mortality in all patients with CRAB infection was 56.1%. Mortality in col-R CRAB and colistin-susceptible (col-S) CRAB infections was 70.0% and 48.6%, respectively (<em>P</em>=0.12). Prior carbapenem use was 56.1%. Prior colistin use before col-R and col-S CRAB infections was not significant (35.0% <em>vs.</em> 27.0%, <em>P</em>=0.53).</p></div><div><h3>Conclusions</h3><p>Our study provides real-world data on highly resistant <em>A. baumannii</em> infections and shares the characteristics of infections with such resistant strains. Unfortunately, carbapenem resistance in <em>A. baumannii</em> is a challenge for intensive care specialists who are faced with few treatment options, and colistin resistance further complicates the problem.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000907/pdfft?md5=86f94941361c491c86f93b2100f0145d&pid=1-s2.0-S2667100X23000907-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139393743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Septic shock due to Capnocytophaga canimorsus treated with IgM-enriched immunoglobulin as adjuvant therapy in an immunocompetent woman 用富含 IgM 的免疫球蛋白作为辅助疗法治疗一名免疫功能正常妇女因卡氏嗜血杆菌引起的脓毒性休克
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.08.003
Josephine Braunsteiner, Stephanie Siedler, Dominik Jarczak, Stefan Kluge, Axel Nierhaus
{"title":"Septic shock due to Capnocytophaga canimorsus treated with IgM-enriched immunoglobulin as adjuvant therapy in an immunocompetent woman","authors":"Josephine Braunsteiner,&nbsp;Stephanie Siedler,&nbsp;Dominik Jarczak,&nbsp;Stefan Kluge,&nbsp;Axel Nierhaus","doi":"10.1016/j.jointm.2023.08.003","DOIUrl":"10.1016/j.jointm.2023.08.003","url":null,"abstract":"","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000592/pdfft?md5=849d3111cbff4d5246b41b4617c81be1&pid=1-s2.0-S2667100X23000592-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134917363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of ePOS score in predicting DNR labeling after ICU admission: A prospective observational study (ePOS-DNR) ePOS 评分在预测 ICU 入院后 DNR 标记方面的诊断准确性:前瞻性观察研究(ePOS-DNR)
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.09.003
Omar E. Ramadan , Ahmed F. Mady , Mohammed A. Al-Odat , Ahmed N. Balshi , Ahmed W. Aletreby , Taisy J. Stephen , Sheena R. Diolaso , Jennifer Q. Gano , Waleed Th. Aletreby

Background

Resuscitation can sometimes be futile and making a do-not-resuscitate (DNR) decision is in the best interest of the patient. The electronic poor outcome screening (ePOS) score was developed to predict 6-month poor outcomes of critically ill patients. We explored the diagnostic accuracy of the ePOS score in predicting DNR decisions in the intensive care unit (ICU).

Methods

This study was conducted at the ICU of a tertiary referral hospital in Saudi Arabia between March and May 2023. Prospectively, we calculated ePOS scores for all eligible consecutive admissions after 48 h in the ICU and recorded the DNR orders. The ability of the score to predict DNR was explored using logistic regression. Youden's ideal cut-off value was calculated using the DeLong method, and different diagnostic accuracy measures were generated with corresponding 95 % confidence intervals (CIs).

Results

We enrolled 857 patients, 125 received a DNR order and 732 did not. The average ePOS score of DNR and non-DNR patients was 28.2±10.7 and 15.2±9.7, respectively. ePOS score, as a predictor of DNR order, had an area under receiver operator characteristic (AUROC) curve of 81.8 % (95% CI: 79.0 to 84.3, P <0.001). Youden's ideal cut-off value >17 was associated with a sensitivity of 87.2 (95% CI: 80.0 to 92.5, P <0.001), specificity of 63.9 (95% CI: 60.3 to 67.4, P <0.001), positive predictive value of 29.2 (95% CI: 24.6 to 33.8, P <0.001), negative predictive value of 96.7 (95% CI: 95.1 to 98.3, P <0.001), and diagnostic odds ratio 12.1 (95% CI: 7.0 to 20.8, P <0.001).

Conclusions

In this study, the ePOS score performed well as a diagnostic test for patients who will be labeled as DNR during their ICU stay. A cut-off score >17 may help guide clinical decisions to withhold or commence resuscitative measures.

背景复苏有时可能是徒劳的,做出不进行复苏(DNR)的决定符合患者的最佳利益。电子不良预后筛查(ePOS)评分是为了预测重症患者 6 个月的不良预后而开发的。我们探讨了 ePOS 评分在预测重症监护病房(ICU)DNR 决定方面的诊断准确性。方法这项研究于 2023 年 3 月至 5 月期间在沙特阿拉伯一家三级转诊医院的重症监护病房进行。我们前瞻性地计算了重症监护室 48 小时后所有符合条件的连续入院患者的 ePOS 分数,并记录了 DNR 命令。我们使用逻辑回归法探讨了该评分预测 DNR 的能力。使用 DeLong 方法计算了尤登理想临界值,并得出了不同的诊断准确性测量值及相应的 95 % 置信区间 (CI)。DNR 和非 DNR 患者的平均 ePOS 评分分别为(28.2±10.7)分和(15.2±9.7)分。ePOS 评分作为 DNR 命令的预测指标,其接收者操作特征曲线下面积(AUROC)为 81.8 %(95% CI:79.0 至 84.3,P <0.001)。Youden理想截断值>17的灵敏度为87.2 (95% CI: 80.0 to 92.5, P <0.001),特异度为63.9 (95% CI: 60.3 to 67.4, P <0.001),阳性预测值为29.2 (95% CI: 24.6 to 33.8, P <0.001),阴性预测值为96.7 (95% CI: 95.1 to 98.3, P <0.001),诊断几率比12.1 (95% CI: 7.0 to 20.8, P <0.001)。结论在这项研究中,ePOS评分作为ICU住院期间将被标记为DNR患者的诊断测试表现良好。截断分数>17可能有助于指导临床决定暂停或开始复苏措施。
{"title":"Diagnostic accuracy of ePOS score in predicting DNR labeling after ICU admission: A prospective observational study (ePOS-DNR)","authors":"Omar E. Ramadan ,&nbsp;Ahmed F. Mady ,&nbsp;Mohammed A. Al-Odat ,&nbsp;Ahmed N. Balshi ,&nbsp;Ahmed W. Aletreby ,&nbsp;Taisy J. Stephen ,&nbsp;Sheena R. Diolaso ,&nbsp;Jennifer Q. Gano ,&nbsp;Waleed Th. Aletreby","doi":"10.1016/j.jointm.2023.09.003","DOIUrl":"10.1016/j.jointm.2023.09.003","url":null,"abstract":"<div><h3>Background</h3><p>Resuscitation can sometimes be futile and making a do-not-resuscitate (DNR) decision is in the best interest of the patient. The electronic poor outcome screening (ePOS) score was developed to predict 6-month poor outcomes of critically ill patients. We explored the diagnostic accuracy of the ePOS score in predicting DNR decisions in the intensive care unit (ICU).</p></div><div><h3>Methods</h3><p>This study was conducted at the ICU of a tertiary referral hospital in Saudi Arabia between March and May 2023. Prospectively, we calculated ePOS scores for all eligible consecutive admissions after 48 h in the ICU and recorded the DNR orders. The ability of the score to predict DNR was explored using logistic regression. Youden's ideal cut-off value was calculated using the DeLong method, and different diagnostic accuracy measures were generated with corresponding 95 % confidence intervals (CIs).</p></div><div><h3>Results</h3><p>We enrolled 857 patients, 125 received a DNR order and 732 did not. The average ePOS score of DNR and non-DNR patients was 28.2±10.7 and 15.2±9.7, respectively. ePOS score, as a predictor of DNR order, had an area under receiver operator characteristic (AUROC) curve of 81.8 % (95% CI: 79.0 to 84.3, <em>P</em> &lt;0.001). Youden's ideal cut-off value &gt;17 was associated with a sensitivity of 87.2 (95% CI: 80.0 to 92.5, <em>P</em> &lt;0.001), specificity of 63.9 (95% CI: 60.3 to 67.4, <em>P</em> &lt;0.001), positive predictive value of 29.2 (95% CI: 24.6 to 33.8, <em>P</em> &lt;0.001), negative predictive value of 96.7 (95% CI: 95.1 to 98.3, <em>P</em> &lt;0.001), and diagnostic odds ratio 12.1 (95% CI: 7.0 to 20.8, <em>P</em> &lt;0.001).</p></div><div><h3>Conclusions</h3><p>In this study, the ePOS score performed well as a diagnostic test for patients who will be labeled as DNR during their ICU stay. A cut-off score &gt;17 may help guide clinical decisions to withhold or commence resuscitative measures.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000798/pdfft?md5=1c3da08ab34201aa2f3d09d3325a9bef&pid=1-s2.0-S2667100X23000798-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135455062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with decreased compliance after on-site extracorporeal membrane oxygenation cannulation for acute respiratory distress syndrome: A retrospective, observational cohort study 急性呼吸窘迫综合征现场体外膜肺氧合插管后依从性下降的相关因素:一项回顾性观察队列研究
Pub Date : 2024-04-01 DOI: 10.1016/j.jointm.2023.09.004
Sylvain Le Pape , Florent Joly , François Arrivé , Jean-Pierre Frat , Maeva Rodriguez , Maïa Joos , Laura Marchasson , Mathilde Wairy , Arnaud W. Thille , Rémi Coudroy

Background

Extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) is systematically associated with decreased respiratory system compliance (CRS). It remains unclear whether transportation to the referral ECMO center, changes in ventilatory mode or settings to achieve ultra-protective ventilation, or the natural evolution of ARDS drives this change in respiratory mechanics. Herein, we assessed the precise moment when CRS decreases after ECMO cannulation and identified factors associated with decreased CRS.

Methods

To rule out the effect of transportation and the different modes of ventilation on CRS, we conducted a retrospective, single-center, observational cohort study from January 2013 to May 2020, on 22 patients with severe ARDS requiring on-site ECMO and ventilated in pressure-controlled mode to achieve ultra-protective ventilation. CRS was assessed at different time points ranging from 12 h before ECMO cannulation to 72 h after ECMO cannulation. The primary outcome was the relative change in CRS between 3 h before and 3 h after ECMO cannulation. The secondary outcomes included variables associated with the relative changes in CRS within the first 3 h after ECMO cannulation and the relative changes in CRS at each time point.

Results

CRS decreased within the first 3 h after ECMO cannulation (−28.3%, 95% confidence interval [CI]: −38.8 to −17.9, P<0.001), while the decrease was mild before and after these first 3 h after ECMO cannulation. To achieve ultra-protective ventilation, respiratory rate decreased in the mean by –13 breaths/min (95% CI: −15 to −11) and driving pressure by −8.3 cmH2O (95% CI: −11.2 to −5.3), resulting in decreased tidal volume by −3.3 mL/kg of predicted body weight (95% CI: −3.9 to −2.6) as compared to before ECMO cannulation (P <0.001 for all). Plateau pressure reduction, driving pressure reduction, and tidal volume reduction were significantly associated with decreased CRS after ECMO cannulation, whereas neither respiratory rate, positive end-expiratory pressure, inspired fraction of oxygen, fluid balance, nor mean airway pressure was associated with decreased CRS.

Conclusions

Decreased driving pressure resulting in lower tidal volume to achieve ultra-protective ventilation after ECMO cannulation was associated with a marked decrease in CRS in ARDS patients with on-site ECMO cannulation.

背景体外膜肺氧合(ECMO)治疗急性呼吸窘迫综合征(ARDS)与呼吸系统顺应性(CRS)下降有系统性关联。目前仍不清楚是转运至转诊 ECMO 中心、为实现超保护通气而改变通气模式或设置,还是 ARDS 的自然演变导致了呼吸力学的这种变化。为了排除转运和不同通气模式对 CRS 的影响,我们在 2013 年 1 月至 2020 年 5 月期间对 22 例需要现场 ECMO 并以压力控制模式通气以实现超保护通气的重度 ARDS 患者进行了一项回顾性、单中心、观察性队列研究。从 ECMO 插管前 12 小时到 ECMO 插管后 72 小时的不同时间点对 CRS 进行了评估。主要结果是 ECMO 插管前 3 小时与插管后 3 小时之间 CRS 的相对变化。次要结果包括与 ECMO 插管后前 3 小时内 CRS 相对变化相关的变量以及每个时间点 CRS 的相对变化。结果 CRS 在 ECMO 插管后前 3 小时内下降(-28.3%,95% 置信区间 [CI]:-38.8 至 -17.9,P<0.001),而在 ECMO 插管后前 3 小时之前和之后下降幅度较小。为实现超保护通气,与 ECMO 插管前相比,呼吸频率平均降低了 -13 次/分(95% CI:-15 至 -11),驱动压力降低了 -8.3 cmH2O(95% CI:-11.2 至 -5.3),潮气量减少了 -3.3 mL/kg(95% CI:-3.9 至 -2.6)(所有数据均为 P<0.001)。ECMO插管后,平台压降低、驱动压降低和潮气量降低与 CRS 下降显著相关,而呼吸频率、呼气末正压、吸入氧分压、液体平衡和平均气道压均与 CRS 下降无关。
{"title":"Factors associated with decreased compliance after on-site extracorporeal membrane oxygenation cannulation for acute respiratory distress syndrome: A retrospective, observational cohort study","authors":"Sylvain Le Pape ,&nbsp;Florent Joly ,&nbsp;François Arrivé ,&nbsp;Jean-Pierre Frat ,&nbsp;Maeva Rodriguez ,&nbsp;Maïa Joos ,&nbsp;Laura Marchasson ,&nbsp;Mathilde Wairy ,&nbsp;Arnaud W. Thille ,&nbsp;Rémi Coudroy","doi":"10.1016/j.jointm.2023.09.004","DOIUrl":"10.1016/j.jointm.2023.09.004","url":null,"abstract":"<div><h3>Background</h3><p>Extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) is systematically associated with decreased respiratory system compliance (CRS). It remains unclear whether transportation to the referral ECMO center, changes in ventilatory mode or settings to achieve ultra-protective ventilation, or the natural evolution of ARDS drives this change in respiratory mechanics. Herein, we assessed the precise moment when CRS decreases after ECMO cannulation and identified factors associated with decreased CRS.</p></div><div><h3>Methods</h3><p>To rule out the effect of transportation and the different modes of ventilation on CRS, we conducted a retrospective, single-center, observational cohort study from January 2013 to May 2020, on 22 patients with severe ARDS requiring on-site ECMO and ventilated in pressure-controlled mode to achieve ultra-protective ventilation. CRS was assessed at different time points ranging from 12 h before ECMO cannulation to 72 h after ECMO cannulation. The primary outcome was the relative change in CRS between 3 h before and 3 h after ECMO cannulation. The secondary outcomes included variables associated with the relative changes in CRS within the first 3 h after ECMO cannulation and the relative changes in CRS at each time point.</p></div><div><h3>Results</h3><p>CRS decreased within the first 3 h after ECMO cannulation (−28.3%, 95% confidence interval [CI]: −38.8 to −17.9, <em>P</em>&lt;0.001), while the decrease was mild before and after these first 3 h after ECMO cannulation. To achieve ultra-protective ventilation, respiratory rate decreased in the mean by –13 breaths/min (95% CI: −15 to −11) and driving pressure by −8.3 cmH<sub>2</sub>O (95% CI: −11.2 to −5.3), resulting in decreased tidal volume by −3.3 mL/kg of predicted body weight (95% CI: −3.9 to −2.6) as compared to before ECMO cannulation (<em>P</em> &lt;0.001 for all). Plateau pressure reduction, driving pressure reduction, and tidal volume reduction were significantly associated with decreased CRS after ECMO cannulation, whereas neither respiratory rate, positive end-expiratory pressure, inspired fraction of oxygen, fluid balance, nor mean airway pressure was associated with decreased CRS.</p></div><div><h3>Conclusions</h3><p>Decreased driving pressure resulting in lower tidal volume to achieve ultra-protective ventilation after ECMO cannulation was associated with a marked decrease in CRS in ARDS patients with on-site ECMO cannulation.</p></div>","PeriodicalId":73799,"journal":{"name":"Journal of intensive medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667100X23000841/pdfft?md5=61183c699b866e26d06227c467462980&pid=1-s2.0-S2667100X23000841-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139023674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of intensive medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1